DISCOVER THE
POSSIBILITIES
with a combination treatment
Not actual patient. BRAFTOVI and
BRAFTOVI + MEKTOVI are approved
for the treatment of adult patients only.
Not actual patient. BRAFTOVI and
BRAFTOVI + MEKTOVI are approved
for the treatment of adult patients only.
IMPORTANT SAFETY
INFORMATION AND USE
FIND OUT MORE
COLLAPSE
BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) may cause serious side effects, including:
Check your skin and tell your healthcare provider right away about any skin changes, including a:
Your healthcare provider should check your skin before treatment, every 2 months during treatment, and for up to 6 months after you stop treatment to look for any new skin cancers.
Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that develop during treatment.
BRAFTOVI (encorafenib) is a prescription medicine used:
BRAFTOVI should not be used to treat people with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF NSCLC. Your healthcare provider will perform a test to make sure that BRAFTOVI or BRAFTOVI with MEKTOVI is right for you.
It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with BRAFTOVI and MEKTOVI if you have certain side effects.
Tell your healthcare team if you are pregnant or plan to become pregnant. BRAFTOVI and MEKTOVI can harm your unborn baby.
Talk to your healthcare team if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment with BRAFTOVI and MEKTOVI and for:
BRAFTOVI may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you.
The most common side effects of BRAFTOVI when taken with MEKTOVI for melanoma include: fatigue, nausea, diarrhea, vomiting, stomach-area (abdominal) pain, and pain or swelling of your joints (arthralgia).
The most common side effects of BRAFTOVI when taken in combination with cetuximab for CRC include: fatigue, nausea, diarrhea, acne-like rash (dermatitis acneiform), stomach-area (abdominal) pain, decreased appetite, pain or swelling of your joints (arthralgia), and rash.
The most common side effects of BRAFTOVI when taken with MEKTOVI for NSCLC include: fatigue, nausea, diarrhea, muscle or joint pain, vomiting, stomach-area (abdominal) pain, blurred vision, loss of vision, or other vision changes, constipation, shortness of breath, rash, and cough.
Before taking BRAFTOVI in combination with MEKTOVI or cetuximab, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. BRAFTOVI and certain other medicines can affect each other, causing side effects or affecting how BRAFTOVI or other medicines work. You should also avoid grapefruit products during treatment with BRAFTOVI.
These are not all of the possible side effects of BRAFTOVI and MEKTOVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch. You may also report side effects to Pfizer Inc. at 1-800-438-1985.
For BRAF positive metastatic melanoma, please see both BRAFTOVI full Prescribing Information, including Medication Guide, and MEKTOVI full Prescribing Information, including Medication Guide, for additional information.
For BRAF positive metastatic colorectal cancer, please see BRAFTOVI full Prescribing Information, including Medication Guide, for additional information.
For BRAF positive metastatic non-small cell lung cancer, please see both BRAFTOVI full Prescribing Information, including Medication Guide, and MEKTOVI full Prescribing Information, including Medication Guide, for additional information.
BRAFTOVI (encorafenib) is a prescription medicine used:
BRAFTOVI should not be used to treat people with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF NSCLC. Your healthcare provider will perform a test to make sure that BRAFTOVI or BRAFTOVI with MEKTOVI is right for you.
It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.
BRAFTOVI (encorafenib) is a prescription medicine used:
BRAFTOVI should not be used to treat people with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF NSCLC. Your healthcare provider will perform a test to make sure that BRAFTOVI or BRAFTOVI with MEKTOVI is right for you.
It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.
BRAFTOVI (encorafenib) is a prescription medicine used:
BRAFTOVI should not be used to treat people with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF NSCLC. Your healthcare provider will perform a test to make sure that BRAFTOVI or BRAFTOVI with MEKTOVI is right for you.
It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.
BRAFTOVI (encorafenib) is a prescription medicine used:
BRAFTOVI should not be used to treat people with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF NSCLC. Your healthcare provider will perform a test to make sure that BRAFTOVI or BRAFTOVI with MEKTOVI is right for you.
It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.
BRAFTOVI (encorafenib) is a prescription medicine used:
BRAFTOVI should not be used to treat people with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF NSCLC. Your healthcare provider will perform a test to make sure that BRAFTOVI or BRAFTOVI with MEKTOVI is right for you.
It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.
BRAFTOVI (encorafenib) is a prescription medicine used:
BRAFTOVI should not be used to treat people with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF NSCLC. Your healthcare provider will perform a test to make sure that BRAFTOVI or BRAFTOVI with MEKTOVI is right for you.
It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.
BRAFTOVI (encorafenib) is a prescription medicine used:
BRAFTOVI should not be used to treat people with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF NSCLC. Your healthcare provider will perform a test to make sure that BRAFTOVI or BRAFTOVI with MEKTOVI is right for you.
It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.
BRAFTOVI (encorafenib) is a prescription medicine used:
BRAFTOVI should not be used to treat people with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF NSCLC. Your healthcare provider will perform a test to make sure that BRAFTOVI or BRAFTOVI with MEKTOVI is right for you.
It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.